Trials / Withdrawn
WithdrawnNCT05676112
Safety of Nintedanib in Real World in China
Safety of Nintedanib in Real World in China: a Non-interventional Study Based on Idiopathic Pulmonary (Interstitial) Fibrosis Registry China Study (PORTRAY) Data
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the incidence rates of adverse drug reactions (ADRs) and fatal adverse events (AEs) among idiopathic pulmonary fibrosis (IPF) patients in China who initiate nintedanib during the study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nintedanib | nintedanib |
| DRUG | pirfenidone | pirfenidone |
Timeline
- Start date
- 2023-12-29
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
- First posted
- 2023-01-09
- Last updated
- 2024-12-10
Source: ClinicalTrials.gov record NCT05676112. Inclusion in this directory is not an endorsement.